TESA – Research Grade GHRH Analog Peptide

TESA (tesamorelin) is a synthetic stabilized analog of the natural hypothalamic peptide growth-hormone-releasing hormone (GHRH), with a specific N-terminal modification that confers protection against the rapid plasma degradation that limits the use of unmodified GHRH in research and clinical contexts. The molecule retains the complete 44-amino-acid GHRH(1-44) sequence — making it a close analog of the full-length natural peptide — and adds a trans-3-hexenoic acid group at the N-terminus that protects against degradation by dipeptidyl peptidase-4 (DPP-4) and other N-terminal proteases. The resulting compound has substantially improved metabolic stability relative to unmodified GHRH while retaining the full-length receptor-engagement profile of the natural hormone.

The conceptual story behind tesamorelin is the convergence of two threads of GHRH research. First is the natural GHRH biology that emerged through the 1980s, beginning with the isolation and characterization of GHRH as a hypothalamic releasing hormone that stimulates growth hormone secretion from pituitary somatotroph cells. Second is the medicinal-chemistry recognition that the N-terminal of GHRH (specifically the Tyr-Ala dipeptide at positions 1-2) is the primary site of proteolytic cleavage by DPP-4, and that N-terminal modifications protecting against this cleavage substantially extend the metabolic stability of the molecule. Tesamorelin was developed at Theratechnologies (a Canadian pharmaceutical company) through the 2000s as a stabilized GHRH analog using a hexenoic-acid N-terminal modification, and the compound was approved by the U.S. FDA in 2010 under the brand name Egrifta for a specific clinical indication.

This page is an educational reference for readers who want to understand what tesamorelin actually is from a peptide-chemistry and pharmacology standpoint, where it came from in the broader GHRH research lineage, what the published literature describes about its receptor-engagement and stability profile, and where it sits in the broader pituitary-axis and somatotroph-research landscapes. It is not a medical-use guide, does not describe any therapy or personal-application protocol, and makes no claims about effects in people who acquire the compound for research purposes. Tesamorelin supplied as a research peptide in this context is intended for laboratory and analytical work only.

Tesamorelin is a synthetic 44-amino-acid peptide built on the complete GHRH(1-44) sequence with a single specific modification: a trans-3-hexenoic acid group attached to the N-terminal tyrosine. The peptide sequence corresponds exactly to the natural human GHRH(1-44) — the full-length form of the hypothalamic releasing hormone secreted by GHRH-producing neurons in the arcuate nucleus and other hypothalamic regions. The C-terminal amidation that is present in the natural full-length GHRH is retained in tesamorelin, and the rest of the sequence is unmodified from the natural human GHRH(1-44).

The defining structural innovation is the trans-3-hexenoic acid N-terminal modification. The natural GHRH(1-44) has a free N-terminal alpha-amine on the tyrosine residue at position 1, and this N-terminal is the primary site of proteolytic cleavage by dipeptidyl peptidase-4 (DPP-4), which removes the N-terminal Tyr-Ala dipeptide and produces an inactive GHRH(3-44) fragment. This DPP-4 cleavage is the principal pathway by which natural GHRH is rapidly inactivated in plasma — the half-life of unmodified GHRH in plasma is on the order of minutes, limiting its practical use as a research or clinical tool. The trans-3-hexenoic acid modification attached to the N-terminal amine blocks DPP-4 access to the cleavage site and substantially extends the plasma half-life.

The receptor-engagement profile of tesamorelin is that of a full GHRH receptor agonist. The compound binds and activates the GHRH receptor (a class B G-protein-coupled receptor expressed prominently on pituitary somatotroph cells) with affinity and efficacy comparable to the natural GHRH, signaling through Gs-coupled adenylyl-cyclase activation and elevation of intracellular cyclic AMP. The downstream signaling cascade in pituitary somatotroph cells leads to stimulation of growth hormone synthesis and secretion through the canonical GHRH-receptor pathway. The retention of the full-length GHRH(1-44) sequence in tesamorelin means that the receptor-engagement profile is closer to that of the natural full-length hormone than to that of the shorter GHRH(1-29) analogs (sermorelin and CJC-1295 with and without DAC) that are also commonly used in GHRH-axis research.

It is worth being specific about what tesamorelin is not. It is not a growth-hormone-secretagogue-receptor (GHSR / ghrelin-receptor) agonist — it does not engage the GHSR receptor used by ghrelin, hexarelin, ipamorelin, and the other "GH secretagogue" research peptides. It is not growth hormone itself — it is the upstream releasing hormone that stimulates pituitary growth hormone secretion. And it is not a depot-style ultra-long-acting analog — its plasma half-life of approximately 30 minutes after subcutaneous administration is substantially extended relative to unmodified GHRH but is short compared to the multi-day half-lives of the lipidated long-acting peptides (semaglutide, cagrilintide, tirzepatide) that dominate the contemporary long-acting peptide landscape.

Tesamorelin's development sits inside the broader history of GHRH research that emerged through the 1980s and the medicinal-chemistry effort to produce stabilized GHRH analogs that began in the same period.

The natural GHRH was isolated and characterized in the early 1980s through work by Roger Guillemin and his collaborators (Guillemin had previously shared the 1977 Nobel Prize in Physiology or Medicine for the original discovery of hypothalamic releasing hormones, particularly TRH). The GHRH-isolation work in the early 1980s characterized GHRH as a 44-amino-acid peptide hormone (in its full-length form, GHRH(1-44)) produced primarily in the arcuate nucleus and other hypothalamic regions and acting on pituitary somatotroph cells through a specific GHRH receptor to stimulate growth hormone synthesis and secretion. The shorter GHRH(1-29) fragment was also characterized as biologically active, with the N-terminal 29 residues constituting the minimal sequence required for receptor activation.

The DPP-4 cleavage of GHRH at the N-terminal Tyr-Ala dipeptide was characterized through the 1980s and 1990s as the primary pathway by which natural GHRH is rapidly inactivated in plasma. The recognition that N-terminal modifications could protect against DPP-4 cleavage motivated several lines of medicinal-chemistry effort to produce stabilized GHRH analogs. The principal strategies included: (1) modification of the alanine at position 2 to a residue that prevents DPP-4 recognition (the strategy used in sermorelin's CJC-1295 derivatives, where the alanine is replaced or the surrounding residues are modified); (2) attachment of a non-amino-acid group to the N-terminal alpha-amine to block DPP-4 access (the strategy used in tesamorelin); and (3) addition of an albumin-binding linker (the strategy used in CJC-1295 with DAC, which adds a maleimide-containing linker to the C-terminus of a stabilized GHRH(1-29) analog).

Theratechnologies, a Canadian pharmaceutical company based in Montreal, developed tesamorelin in the 2000s as a stabilized full-length GHRH(1-44) analog using the trans-3-hexenoic acid N-terminal modification strategy. The compound was characterized in extensive preclinical and clinical research and was approved by the U.S. FDA in 2010 under the brand name Egrifta for a specific clinical indication in adult HIV-infected patients with lipodystrophy. The approval represented the first GHRH analog to reach clinical use as an approved therapeutic, complementing the earlier use of sermorelin (which had been approved in the late 1990s for a different specific indication).

The broader GHRH-analog research field has continued to develop, with multiple stabilized GHRH(1-29) analogs (including the CJC-1295 with-DAC and without-DAC variants), the full-length GHRH(1-44) analog tesamorelin, and various other research-peptide derivatives. The GHRH-analog field complements and overlaps with the GH-secretagogue field (anchored by ipamorelin and the other GHSR-receptor agonists) in the broader pituitary growth-hormone-axis research landscape.

Important milestones include the early-1980s isolation of GHRH by Guillemin and collaborators, the 1980s-1990s characterization of DPP-4 cleavage as the primary GHRH inactivation pathway, the late-1990s sermorelin approval for a specific clinical indication, the 2000s development of tesamorelin at Theratechnologies, and the 2010 tesamorelin approval under the Egrifta brand.

The science of tesamorelin is anchored in three connected areas: the natural biology of GHRH as a hypothalamic releasing hormone, the GHRH receptor and pituitary somatotroph biology that mediate GHRH's effects, and the medicinal chemistry of the trans-3-hexenoic acid N-terminal modification that confers tesamorelin's stability advantage.

• Tesamorelin is a stabilized 44-amino-acid GHRH(1-44) analog with a trans-3-hexenoic acid N-terminal modification that prevents DPP-4 cleavage.
• Retains the complete full-length GHRH(1-44) sequence, distinguishing it from the GHRH(1-29)-based sermorelin and CJC-1295 derivatives.
• Developed at Theratechnologies in the 2000s; approved by the U.S. FDA in 2010 under the brand name Egrifta for a specific clinical indication.
• Acts at the GHRH receptor (class B GPCR) on pituitary somatotroph cells to stimulate pulsatile growth hormone secretion through Gs / cAMP / PKA / CREB signaling.
• Distinct from GH-secretagogue research peptides (ipamorelin, hexarelin) that act at the GHSR / ghrelin receptor rather than at the GHRH receptor.

Structurally, tesamorelin is a 44-amino-acid linear peptide built on the complete natural GHRH(1-44) sequence with a trans-3-hexenoic acid group attached to the N-terminal tyrosine. The molecular mass of tesamorelin is approximately 5196 daltons in the free-base form. The C-terminal amidation that is present in the natural full-length GHRH is retained in tesamorelin, with the C-terminal amide replacing what would otherwise be the free C-terminal carboxylic acid.

The trans-3-hexenoic acid N-terminal modification is the defining structural feature. The hexenoic-acid group is a six-carbon acyl chain with a trans double bond at the 3-position, attached to the N-terminal alpha-amine of the tyrosine at position 1 through an amide bond. The modification adds a small non-amino-acid acyl group to the N-terminus, blocking the DPP-4 cleavage site (which would otherwise cleave the N-terminal Tyr-Ala dipeptide) and substantially extending the plasma half-life of the molecule. The hexenoic-acid group is small relative to the long fatty-acid side chains used in lipidated long-acting peptides (such as semaglutide's C18 di-acid), and tesamorelin does not have albumin-binding lipidation pharmacology — the hexenoic-acid modification is a stability modification rather than a pharmacokinetic-extension modification.

The complete 44-amino-acid backbone provides the full GHRH receptor-binding surface and contributes additional structural stability beyond what the N-terminal 29 residues alone would provide. The peptide is a linear molecule without disulfide bridges or other cyclic constraints (GHRH does not have cysteines and therefore does not form disulfide-bridged loops in the way that, for example, somatostatin or oxytocin does).

The combined structural design — full-length GHRH(1-44) scaffold for complete receptor engagement, C-terminal amidation for matching the natural hormone chemistry, trans-3-hexenoic acid N-terminal modification for DPP-4-cleavage protection — produces a molecule with the receptor-engagement profile of natural GHRH and the metabolic stability needed for practical research and clinical use. The plasma half-life of tesamorelin after subcutaneous administration is on the order of 30 minutes — substantially longer than the few-minute half-life of unmodified GHRH but much shorter than the multi-day half-lives of the lipidated long-acting peptides.

Tesamorelin is studied in laboratory contexts that span GHRH receptor pharmacology, pituitary growth-hormone-axis research, comparative pharmacology of GHRH analogs and GH secretagogues, and broader metabolic-research areas connected to growth-hormone-axis signaling.

In GHRH receptor pharmacology, tesamorelin serves as a reference stabilized full-length GHRH analog for studies on receptor binding and signaling at the GHRH receptor, on the downstream Gs / cyclic AMP / PKA / CREB cascade activated by GHRH-receptor engagement, on the comparative pharmacology of full-length GHRH(1-44) analogs versus shorter GHRH(1-29) analogs, and on the structure-activity relationships within the broader GHRH-analog research lineage.

In pituitary growth-hormone-axis research, tesamorelin appears in studies on the pulsatile growth hormone secretion produced by GHRH-receptor stimulation, on the integration of GHRH-receptor signaling with the somatostatin counter-regulatory signaling that contributes to the pulsatile growth-hormone-secretion pattern, on the differences and similarities between GHRH-mediated growth hormone secretion and ghrelin-receptor-mediated growth hormone secretion (the GH-secretagogue pharmacology), and on the integrated pharmacology of the growth-hormone-axis at the pituitary, hepatic, and peripheral tissue levels.

In comparative GHRH-analog and GH-secretagogue research, tesamorelin is used as a reference compound alongside sermorelin (a shorter GHRH(1-29) analog with simpler chemistry), the CJC-1295 derivatives (GHRH(1-29) analogs with stabilizing modifications including the albumin-binding DAC linker variant), and the GH-secretagogue research peptides ipamorelin and hexarelin (which act at the GHSR / ghrelin receptor rather than at the GHRH receptor). The comparative pharmacology characterizes the differences between GHRH-receptor engagement and GHSR-receptor engagement in producing growth hormone secretion, and the differences between full-length GHRH(1-44) and GHRH(1-29) scaffolds.

In broader metabolic-research areas, tesamorelin appears in studies on the integration of growth-hormone-axis signaling with metabolic regulation, particularly on the effects of stimulated growth hormone secretion on body composition, on lipid metabolism, and on related metabolic endpoints. The clinical-research literature on tesamorelin in the Egrifta approval context addresses specific metabolic-research questions that are part of this broader integration of growth-hormone-axis and metabolic pharmacology.

Across all of these contexts, the research applications in the research-peptide supply context are laboratory and analytical in nature. The compound's status as an approved pharmaceutical under the Egrifta brand for a specific clinical indication is a separate channel; research-peptide use is intended for laboratory and analytical work distinct from clinical use of the approved product.

Tesamorelin sits within the broader landscape of GHRH-analog and growth-hormone-axis research peptides, with related but distinguishable comparators across the GHRH-analog, GH-secretagogue, and natural-hormone categories.

Tesamorelin is a synthetic stabilized analog of the natural hypothalamic peptide growth-hormone-releasing hormone (GHRH), built on the complete 44-amino-acid GHRH(1-44) scaffold with a trans-3-hexenoic acid N-terminal modification that blocks DPP-4 cleavage and substantially extends the plasma half-life relative to unmodified GHRH. The compound was developed at Theratechnologies (a Canadian pharmaceutical company) in the 2000s and was approved by the U.S. FDA in 2010 under the brand name Egrifta for a specific clinical indication in adult HIV-infected patients with lipodystrophy.

The receptor-engagement profile is that of a full GHRH receptor agonist. The compound binds and activates the GHRH receptor (a class B G-protein-coupled receptor) on pituitary somatotroph cells with affinity and efficacy comparable to natural GHRH, signaling through Gs-coupled adenylyl-cyclase activation and elevation of intracellular cyclic AMP, with downstream effects on growth hormone gene transcription, synthesis, and pulsatile secretion. The retention of the full-length GHRH(1-44) sequence distinguishes tesamorelin from the shorter GHRH(1-29) analogs (sermorelin and the CJC-1295 with-and-without-DAC variants) that are also commonly used in GHRH-axis research.

The DPP-4-cleavage-protection from the N-terminal hexenoic-acid modification produces a plasma half-life of approximately 30 minutes — substantially longer than the few-minute half-life of unmodified GHRH but much shorter than the multi-day half-lives of the contemporary lipidated long-acting peptides. The half-life profile supports once-daily dosing and produces pulsatile growth-hormone-stimulation pharmacology that approximates the natural pulsatile pattern, distinct from the more sustained engagement produced by the albumin-binding-linker CJC-1295 with-DAC variant.

Tesamorelin's published research footprint spans GHRH receptor pharmacology, pituitary growth-hormone-axis research, comparative pharmacology of GHRH analogs and GH secretagogues, and broader metabolic-research areas connected to growth-hormone-axis signaling. The compound appears in many research contexts as a reference stabilized full-length GHRH analog with a well-defined receptor-engagement profile and a well-characterized stability advantage relative to unmodified GHRH.

For students, researchers, and curious readers approaching tesamorelin for the first time, the most accurate framing is of a thoughtfully engineered stabilized full-length GHRH(1-44) analog with a defined N-terminal modification strategy, an approved-product status for a specific clinical indication, and a well-established position in the broader pituitary growth-hormone-axis research landscape — distinguished from the GHRH(1-29)-based analogs by the full-length scaffold choice, distinguished from the GH-secretagogue research peptides by the GHRH-receptor (rather than GHSR / ghrelin-receptor) target, and distinguished from direct growth-hormone administration by the upstream pituitary-stimulation rather than direct-receptor-engagement mechanism.